GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genovis AB (OSTO:GENO) » Definitions » Institutional Ownership

Genovis AB (OSTO:GENO) Institutional Ownership : 28.82% (As of May. 04, 2025)


View and export this data going back to 2005. Start your Free Trial

What is Genovis AB Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Genovis AB's institutional ownership is 28.82%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Genovis AB's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Genovis AB's Float Percentage Of Total Shares Outstanding is 0.00%.


Genovis AB Institutional Ownership Historical Data

The historical data trend for Genovis AB's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genovis AB Institutional Ownership Chart

Genovis AB Historical Data

The historical data trend for Genovis AB can be seen below:

2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-03-31
Institutional Ownership 24.82 24.58 24.59 24.69 27.09 26.77 27.09 27.10 29.13 28.82

Genovis AB Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Genovis AB Business Description

Traded in Other Exchanges
Address
Scheelevagen 2, Box 790, Lund, SWE, SE-220 07
Genovis AB provides enzymes and technologies for the analytical characterization and conjugation of biopharmaceuticals. The principal activities of the company are to develop, produce, and market tools for developing new drugs and diagnostics. Its product line comprises GingisREX, FabRICATOR, GlyCLICK, GingisKHAN, GlycINATOR, Fabulous, lgGZERO, and Enzymes for O-glycan. The company's main product category consists of Enzymes and Antibodies. Geographically its segments include Sweden and the rest of the world.

Genovis AB Headlines

No Headlines